R R

What Is a Drug Efflux Pump Inhibitor?

A drug efflux pump inhibitor is a substance that reduces the activity of transport proteins that move drugs out of cells. Efflux pumps normally protect tissues by exporting foreign compounds and also influence drug absorption, distribution, and elimination. Examples of relevant transporters include P-glycoprotein in human tissues and multidrug pumps in bacteria or cancer cells. Inhibiting these pumps can increase the amount of a drug that remains inside a cell or crosses a biological barrier.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is a Drug Efflux Pump Inhibitor?

A drug efflux pump inhibitor is a substance that reduces the activity of transport proteins that move drugs out of cells. Efflux pumps normally protect tissues by exporting foreign compounds and also influence drug absorption, distribution, and elimination. Examples of relevant transporters include P-glycoprotein in human tissues and multidrug pumps in bacteria or cancer cells. Inhibiting these pumps can increase the amount of a drug that remains inside a cell or crosses a biological barrier.

read more about drug efflux pump inhibitor ...

Copy this HTML:

Copy HTML Copied!

What Are Drug Efflux Pump Inhibitors Used For?

Efflux inhibition is studied as a way to improve drug absorption and overcome resistance in cancer cells or microorganisms. In clinical pharmacology, some medicines inhibit transporters such as P-glycoprotein and thereby change the exposure of other drugs. Most bacterial efflux pump inhibitors remain experimental rather than approved treatments specifically for reversing antibiotic resistance. The usefulness of inhibition depends on the transporter, tissue, substrate drug, and degree of selectivity.

How Do Drug Efflux Pump Inhibitors Work?

An inhibitor can bind directly to a pump, compete with transported drugs, disrupt the energy source that powers transport, or reduce pump expression or assembly. Blocking export raises the intracellular concentration of susceptible drugs. In the intestine, transporter inhibition can also increase the amount of a substrate that enters the bloodstream. The effect can be beneficial in a planned combination or harmful when it causes unintended drug accumulation.

How Do Efflux Pumps Cause Drug Resistance?

Cells can produce more efflux pumps or increase their activity after genetic or regulatory changes. The pumps lower intracellular drug concentrations before the medicine can fully reach its target. Bacteria can export several antibiotic classes, while cancer cells can remove multiple anticancer drugs through transporters such as P-glycoprotein. Efflux is one resistance mechanism and can occur alongside target changes, drug inactivation, or reduced drug entry.

What Are the Side Effects and Interaction Risks?

Efflux pump inhibition can increase blood or tissue concentrations of drugs with narrow safety margins. The resulting interaction can raise the risk of bleeding, sedation, abnormal heart rhythms, organ toxicity, or other substrate-specific adverse effects. Some inhibitors also affect metabolic enzymes, making the interaction more complex. Dose adjustment, avoidance, or clinical monitoring can be required when a strong transporter inhibitor is combined with a sensitive substrate.

Frequently Asked Questions About Drug Efflux Pump Inhibitors

What is P-glycoprotein?

P-glycoprotein is an efflux transporter found in the intestine, liver, kidneys, blood-brain barrier, and other tissues. It pumps many drugs and foreign compounds out of cells.

Can an efflux pump inhibitor overcome antibiotic resistance?

It can restore or improve antibiotic activity in laboratory and experimental settings when efflux is a major resistance mechanism. No inhibitor can overcome every form of antibiotic resistance.

Are drug efflux pump inhibitors approved medicines?

Some approved medicines inhibit transporters as part of their pharmacologic profile and cause clinically relevant interactions. Many compounds designed specifically to reverse bacterial or cancer multidrug resistance remain investigational.

Can efflux pump inhibition increase drug toxicity?

Yes. Blocking drug export can increase systemic or intracellular exposure to a substrate. The risk depends on the inhibitor strength, drug dose, therapeutic window, and patient factors.

References

M12 Drug Interaction Studies. U.S. Food and Drug Administration. https://www.fda.gov/media/161199/download. Date Accessed August 6, 2026.

Table of Substrates, Inhibitors and Inducers. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Date Accessed August 6, 2026.

Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance. Microbiology Spectrum (PubMed Central). https://pmc.ncbi.nlm.nih.gov/articles/PMC10892612/. Date Accessed August 6, 2026.

Efflux Pump Inhibitors for Bacterial Pathogens: From Bench to Bedside. Indian Journal of Medical Research (PubMed Central). https://pmc.ncbi.nlm.nih.gov/articles/PMC6563736/. Date Accessed August 6, 2026.

Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. Journal of Medicinal Chemistry (PubMed Central). https://pmc.ncbi.nlm.nih.gov/articles/PMC6281405/. Date Accessed August 6, 2026.